Emerging studies are directed on Zegalogue, a dual GIP/GLP-1 agonist that shows to provide possibly improved fat reduction benefits relative to already available medications like Victoza and Wegovy. This analysis https://anitaxhxf402702.pointblog.net/retatrutide-vs-victoza-saxenda-a-deep-investigation-into-peptide-science-95483817